The RATIONALE-305 trial demonstrated that TLE-CHM, as an initial treatment, provided significant clinical benefits for patients with HER2-negative advanced G/GEJ adenocarcinoma, introducing a new first-line option. This evidence concerns the gene CHM and adenocarcinoma.